Intellia Therapeutics Inc

NTLA: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
>xhLOCK|c@LOCK|f!M$#L

Intellia Earnings: Gene Editing Pipeline Continues to Make Progress; Positive Long-Term Outlook

Intellia reported $14.2 million in collaboration revenue in the second quarter, and the company's phase 3 pipeline continues to enroll patients in trials for hereditary angioedema and ATTR with cardiomyopathy and polyneuropathy.

Sponsor Center